CFTR and cystic fibrosis: On the other hand, the variability in the clinical response of patients to these new treatments [29,30] and the existence of a cohort of CF patients lacking the CFTR protein (class 1 mutations for instance) underscores the urgent need of new therapies aimed at developing alternative anion transport pathways independent of CFTR.